Concepedia

Publication | Open Access

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

DOIFull Paper Access

312

Citations

36

References

2011

Year

Carol Aghajanian, Michael W. Sill, Kathleen M. Darcy, Benjamin E. Greer, D. Scott McMeekin, Peter G. Rose, Jacob Rotmensch, Mack N. Barnes, Parviz Hanjani, Kimberly K. Leslie
Journal of Clinical Oncology

Abstract

Bevacizumab is well tolerated and active based on PFS at 6 months in recurrent or persistent EMC and warrants further investigation.

References

YearCitations

Page 1